Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis

References

• Biradar SV, Patil AR, Sudarsan GV, Pokharkar VB. A comparative study of approaches used to improve solubility of roxithromycin. Powder Technol 2006; 169(24)22–32
   Google Scholar
• Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerolization performance. J Control Rel 2001; 70: 329–39
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C. Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241–9
   Google Scholar
• Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res 2007; 24(3)411–37
   PubMed Web of Science ®Google Scholar
• Coates MS, Chan HK, Fletcher DF, Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res 2007; 24(8)1450–6
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V. Safety of Intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9(4)28–37
   PubMed Web of Science ®Google Scholar
• Cruz L, Fattal E, Tasso L, Freitas GC, Carregaro AB, Guterres SS, Pohlmann AR, Tsapis N. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release 2011; 152(3)370–5
   PubMed Web of Science ®Google Scholar
• Dai WG, Dong LC, Song WQ. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int J Pharm 2007; 342: 201–7
   PubMed Web of Science ®Google Scholar
• Dalvi SV, khopadhyay M. A novel process for precipitation of ultra-fine particles using sub-critical CO2. Powder Tech 2009; 195(3)190–5
   Web of Science ®Google Scholar
• Dong Y, Ng WK, Shen S, Kim S, Tan Reginald BH. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm 2009; 375: 84–8
   PubMed Web of Science ®Google Scholar
• Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale HBJ. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm 2009; 370: 167–74
   PubMed Web of Science ®Google Scholar
• Finlay WH. Mechanics of inhaled pharmaceutical aerosols: An introduction. Academic Press, New York 2001
   Google Scholar
• Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 2008; 355: 321–7
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Hickey AJ. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv Drug Delivery Rev 2002; 54: 1491–504
   PubMed Web of Science ®Google Scholar
• Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005; 25: 427–37
   PubMed Web of Science ®Google Scholar
• Hardy JG, Chadawick TS. Sustained release drug delivery to the lungs. Clin Pharmacokinet 2000; 39: 1–4
   PubMed Web of Science ®Google Scholar
• Hartwig S, Heike GB. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 2004; 278: 187–95
   PubMed Web of Science ®Google Scholar
• Hezave AZ, Esmaeilzadeh F. Micronization of drug particles via RESS proces. J Supercrit Fluids 2010; 52(1)84–98
   Web of Science ®Google Scholar
• Katsumi H, Takashima M, Sano J, Nishiyama K, Kitamura N, Sakane T, Hibi T, Yamamoto A. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: Evaluation of absorption, safety, and effects after intrapulmonary administration in rats. J Pharm Sci 2011; 100(9)3783–92
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J Clin Pharmacol 2003; 56: 588–99
   Web of Science ®Google Scholar
• Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci 2005; 24(5)441–9
   PubMed Web of Science ®Google Scholar
• Lenth RV. Response-surface methods in R, using RSM. J Stat Software 2009; 32(7)1–17
   Web of Science ®Google Scholar
• Lin SY, Kawashima Y. The influence of three poly (-oxtethylene) poly (oxypropylene), surface-active block copolymers on the solubility behavior of indomethacin. Pharm Acta Helv 1985; 60: 339–44
   PubMedGoogle Scholar
• Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm 2009; 379: 181–6
   PubMed Web of Science ®Google Scholar
• Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol 1998; 1(9)394–8
   Google Scholar
• Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm 2009; 370: 202–9
   PubMed Web of Science ®Google Scholar
• Meyers RH, Montgomery DC. Response surface methodology., 2nd. Wiley-Interscience, New York 2002
   Google Scholar
• Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293–304
   PubMed Web of Science ®Google Scholar
• Niwa T, Shimabara H, Kondo M, Danjo K. Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle. Int J Pharm 2009; 382: 88–97
   PubMed Web of Science ®Google Scholar
• Palelu NR, 2004. Inhalation administration of bisphosphonates. US Patent 6743414
   Google Scholar
• Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother 2005; 55: 430–5
   PubMed Web of Science ®Google Scholar
• Rao R, Markovic S, Anderson P. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 2003; 3: 239–50
   PubMed Web of Science ®Google Scholar
• Rogueda PGA, Traini D. The nanoscale in pulmonary delivery: Part 1. deposition, fate, toxicology and effects. Expert Opin Drug Discovery 2007; 4(6)595–606
   Google Scholar
• Russell RGG. Bisphosphonates: Mode of action and pharmacology. Pediatrics 2007; 119: S150–62
   PubMed Web of Science ®Google Scholar
• Sham JO, Zhang Y, Finlay WH, Roa WH, Raimar L. Formulation and characterization of spray dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 2004; 269: 457–67
   PubMed Web of Science ®Google Scholar
• Sharma P, Denny WA, Garg S. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int J Pharm 2009; 380: 40–8
   PubMed Web of Science ®Google Scholar
• Tozuka Y, Miyazaki Y, Takeuchi H. A combinational supercritical CO2 system for nanoparticle preparation of indomethacin. Int J Pharm 2010; 386: 243–8
   PubMed Web of Science ®Google Scholar
• Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009a; 380: 216–22
   PubMed Web of Science ®Google Scholar
• Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009b; 377: 185–98
   PubMed Web of Science ®Google Scholar
• Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm 2009; 374: 106–13
   PubMed Web of Science ®Google Scholar
• Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, Yun Y. Preparation of amorphous cefuroxime axetil nanoparticles by controlled precipitation method without surfactants. Int J Pharm 2006; 323: 153–60
   PubMed Web of Science ®Google Scholar